Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

3
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
3
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

4
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
4
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

4
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
4
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

5
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
5
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

3
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
3
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

4
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
4

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hidden Infections, Emerging Resistance: Underdiagnosed Plasmodium vivax and Multidrug Resistance-1 (pvmdr1) Gene Amplification in the Guiana Shield.

The Journal of infectious diseases·2026
Same author

Prevalence in Northern Angola of Cytochrome P450 (CYP) 2C8 Alleles Associated with Amodiaquine Decreased Metabolism.

The American journal of tropical medicine and hygiene·2026
Same author

Trajectory of <i>Plasmodium falciparum</i> Molecular Markers of Amodiaquine Resistance in São Tomé and Príncipe.

Open forum infectious diseases·2025
Same author

How CYP2D6 Polymorphism Modulates the Community-Wide Risk of Plasmodium vivax Infection: A Panel Study in Amazonian Brazil.

The Journal of infectious diseases·2025
Same author

Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections.

The Journal of infectious diseases·2025
Same author

Decreased dihydroartemisinin-piperaquine protection against recurrent malaria associated with Plasmodium falciparum plasmepsin 3 copy number variation in Africa.

Nature communications·2025

Related Experiment Video

Updated: Feb 14, 2026

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster
06:27

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster

Published on: February 24, 2023

1.1K

Amodiaquine pharmacogenetics.

Jose Pedro Gil1

  • 1Karolinska Institutet, Retzius väg 10, plan 5, 171 77 Stockholm, Sweden. jose.pedro.gil@medks.ki.se

Pharmacogenomics
|October 16, 2008
PubMed
Summary
This summary is machine-generated.

Amodiaquine, a key malaria drug, is metabolized by CYP2C8. Understanding how CYP2C8 gene variations affect amodiaquine side effects is crucial for patient safety and personalized medicine.

More Related Videos

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K
The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation
08:44

The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation

Published on: December 2, 2013

11.7K

Related Experiment Videos

Last Updated: Feb 14, 2026

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster
06:27

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster

Published on: February 24, 2023

1.1K
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K
The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation
08:44

The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation

Published on: December 2, 2013

11.7K

Area of Science:

  • Pharmacogenetics
  • Malaria Therapeutics
  • Drug Metabolism

Background:

  • Amodiaquine is a vital component of combination therapies for malaria control.
  • Hepatic metabolism of amodiaquine produces its active metabolite, desethylamodiaquine.
  • CYP2C8, a polymorphic enzyme, is primarily responsible for amodiaquine metabolism.

Purpose of the Study:

  • To investigate the relationship between CYP2C8 genetic variations and amodiaquine's efficacy and safety.
  • To highlight the importance of pharmacogenetic knowledge for amodiaquine use.
  • To lay the groundwork for personalized medicine approaches in malaria treatment.

Main Methods:

  • Analysis of amodiaquine metabolism pathways.
  • Review of amodiaquine-associated side effects.
  • Exploration of CYP2C8 polymorphism impact.

Main Results:

  • Amodiaquine metabolism is significantly influenced by the CYP2C8 enzyme.
  • CYP2C8 genetic variations are likely linked to amodiaquine's adverse effects.
  • Both rare serious and frequent mild side effects are observed.

Conclusions:

  • Pharmacogenetic insights into CYP2C8 are essential for amodiaquine pharmacovigilance.
  • Understanding these genetic factors is a critical step towards personalized amodiaquine therapy.
  • This knowledge supports safer and more effective malaria treatment strategies.